Journal article
Hashan Jayarathne, Wanqing Liu, M. Sadagurski
Aging, 2023
Aging, 2023
Semantic Scholar
DOI
PubMedCentral
PubMed
Cite
Cite
APA
Click to copy
Jayarathne, H., Liu, W., & Sadagurski, M. (2023). Repurposing Canagliflozin to target brain aging. Aging.
Chicago/Turabian
Click to copy
Jayarathne, Hashan, Wanqing Liu, and M. Sadagurski. “Repurposing Canagliflozin to Target Brain Aging.” Aging (2023).
MLA
Click to copy
Jayarathne, Hashan, et al. “Repurposing Canagliflozin to Target Brain Aging.” Aging, 2023.
BibTeX Click to copy
@article{hashan2023a,
title = {Repurposing Canagliflozin to target brain aging},
year = {2023},
journal = {Aging},
author = {Jayarathne, Hashan and Liu, Wanqing and Sadagurski, M.}
}
Abstract
2367 AGING There is a continuous search for pharmacological and nutritional interventions that slow aging. Caloric restriction (CR) is the most intensively studied nutrient intervention that extended lifespan. Anti-diabetic drugs that improve glucose control, reduce postprandial glucose levels, and maintain proper glucose homeostasis can potentially increase lifespan. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are unique anti-diabetic agents commonly used for the treatment of type-2 diabetes mellitus (T2DM). Their pleiotropic effects include a reduction in cardiovascular disease and allcause mortality, which are independent of diabetes [1]. Recent studies by the Interventions Testing Program (ITP) have shown that SGLT2i and Canagliflozin extended the median survival of male mice by 14%, and retard age-related lesions in male mice without an effect on females [2, 3].